中国药科大学学报2024，Vol.55Issue(1)：63-72,10.DOI:10.11665/j.issn.1000-5048.2023121103
布鲁顿酪氨酸激酶(BTK)抑制剂在治疗炎症免疫性疾病中的研究进展
Research progress of Bruton's tyrosine kinase(BTK)inhibitors in the treatment of inflammatory and immune-mediated diseases
任玮杰 1岑丽芳 1邹毅1
作者信息
- 1. 中国药科大学药学院, 南京 211198
- 折叠
摘要
Abstract
Bruton's tyrosine kinase(BTK),a cytoplasmic tyrosine kinase,plays a central role in the activation of B cells and granulocytes,operating downstream of B cell and Fcγ receptors,and is considered an attractive target for treating autoimmune diseases.Preclinical investigations have demonstrated that inhibition of BTK activity holds promise as a potential therapeutic strategy for inflammatory immune responses such as autoimmune diseases and allergies.This review provides an overview of the mechanisms by which BTK contributes to immune-related diseases and summarizes current research on the development of BTK inhibitors for treating these conditions,aiming to offer novel insights into non-oncology applications for BTK inhibitors.关键词
布鲁顿酪氨酸激酶/炎症免疫/自身免疫性疾病/过敏/临床研究Key words
BTK/inflammatory immunity/autoimmune diseases/allergy/clinical research分类
医药卫生引用本文复制引用
任玮杰,岑丽芳,邹毅..布鲁顿酪氨酸激酶(BTK)抑制剂在治疗炎症免疫性疾病中的研究进展[J].中国药科大学学报,2024,55(1):63-72,10.
